- Home
- NIE vs DCTH Comparison
NIE vs DCTH Comparison
Compare NIE & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIE
- DCTH
- Stock Information
- Founded
- NIE 2007
- DCTH 1988
- Country
- NIE United States
- DCTH United States
- Employees
- NIE N/A
- DCTH N/A
- Industry
- NIE Investment Managers
- DCTH Medical/Dental Instruments
- Sector
- NIE Finance
- DCTH Health Care
- Exchange
- NIE Nasdaq
- DCTH Nasdaq
- Market Cap
- NIE 697.4M
- DCTH 630.4M
- IPO Year
- NIE N/A
- DCTH N/A
- Fundamental
- Price
- NIE $22.80
- DCTH $13.85
- Analyst Decision
- NIE
- DCTH Strong Buy
- Analyst Count
- NIE 0
- DCTH 4
- Target Price
- NIE N/A
- DCTH $24.00
- AVG Volume (30 Days)
- NIE 70.5K
- DCTH 508.4K
- Earning Date
- NIE 01-01-0001
- DCTH 08-04-2025
- Dividend Yield
- NIE 9.04%
- DCTH N/A
- EPS Growth
- NIE N/A
- DCTH N/A
- EPS
- NIE N/A
- DCTH N/A
- Revenue
- NIE N/A
- DCTH $53,850,000.00
- Revenue This Year
- NIE N/A
- DCTH $155.42
- Revenue Next Year
- NIE N/A
- DCTH $37.93
- P/E Ratio
- NIE N/A
- DCTH N/A
- Revenue Growth
- NIE N/A
- DCTH 1068.87
- 52 Week Low
- NIE $18.61
- DCTH $7.17
- 52 Week High
- NIE $22.47
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- NIE 44.96
- DCTH 37.03
- Support Level
- NIE $22.74
- DCTH $15.72
- Resistance Level
- NIE $23.20
- DCTH $17.35
- Average True Range (ATR)
- NIE 0.29
- DCTH 0.74
- MACD
- NIE -0.11
- DCTH -0.40
- Stochastic Oscillator
- NIE 5.69
- DCTH 2.23
About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments such as aerospace and defense, banks, IT services, software, and others.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.